Stock DXR DAXOR CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Daxor Corporation Nyse

Equities

DXR

US2394671034

Delayed Nyse
Other stock markets
 10:17:03 02/07/2024 pm IST 		5-day change 1st Jan Change
8.76 USD -2.77% Intraday chart for Daxor Corporation -0.79% -8.75%
05/06 Daxor Corporation Appoints John L. Jefferies as Chief Medical Officer CI
16/04 Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion CI

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor?s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
CI
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
CI
Daxor to Acquire Volumex, Megatope to Increase Diagnostics Suite
MT
Daxor Corporation has entered into a definitive agreement to acquire Volumex®, Megatope® and Glofil® from Iso-Tex Diagnostics, Inc.
CI
Daxor Corporation Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Daxor Corporation Announces Sales to Three New Hospitals Furthering Expansion of Its User Base
CI
Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis
CI
Daxor Corporation Announces Two Significant New Customer Transactions with Daxor's BVA-100 in January 2024
CI
Daxor Corporation Submits Dual 510(K)/CLIA-Waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer
CI
Daxor Corporation Announces the Presentation of Data from a Phase I National Institute of Health Sponsored Randomized Control Trial from Two Veterans Affairs Medical Centers
CI
Daxor Corporation Announces New Data from Banner University Medicine Demonstrating Effectiveness of Bva-100 Use in Ambulatory Heart Failure Patients Presented At Heart Failure Annual Scientific Meeting
CI
Daxor Corporation Reports Earnings Results for the Half Year Ended June 30, 2023
CI
JACC-HF Reports Successful Heart Failure Trial with Daxor BVA-100®
CI
Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy
CI
Daxor Corporation Announces Further Acquisitions and Increased Utilization of Its Bva 100(R) Blood Volume Diagnostic Throughout the U.S
CI
Daxor Corporation Announces Pilot Randomized Controlled Trial Validates Daxor BVA-100 Diagnostic for Heart Failure Patients
CI
Daxor Corporation Study Demonstrates Significant Clinical Utility of Daxor's Blood Volume (Bva-100(R)) Diagnostic in the Evaluation of Heart Failure
CI
Daxor Corporation Announces New Data from the Mayo Clinic in Rochester, NY Validating the Benefits of the company’s BVA-100 Blood Test for Patients with Heart Failure
CI
Daxor Corporation Announces New Data Validating Benefits of BVA-100 Diagnostic Blood Test in Reducing Hospital Length of Stay for Heart Failure (HF) Patients
CI
Daxor Corporation Announces New Data Shows 85% Reduction in One-Year Mortality for Medicare Heart Failure Patients with BVA-Guided Care
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. DXR Stock
  4. DXR Stock
  5. News Daxor Corporation
  6. Highlights